The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
February 13th 2025
Patients with adenomas had a greater risk of colorectal cancer, and advanced adenomas were linked to a greater risk of cancer-related and all-cause mortality.
Vonoprazan for the Treatment of Erosive Esophagitis: A Randomized Controlled Trial
December 6th 2023While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.
SEQUENCE: Comparing Risankizumab to Ustekinumab in Crohn’s Disease
December 6th 2023Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.
ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-α for Ulcerative Colitis
December 2nd 2023Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.
Black Patients Receive Less C Diff Tests Despite Similar Positivity Rates to White Patients
November 27th 2023A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.
Study Identifies Predictors of Fibromyalgia, Chronic Fatigue in IBS Patients
October 31st 2023A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared to those without IBS.